After the treatments, the apoptotic counts were effectively increased and formononetin treatment contributed to the decrease in Bcl-2 protein level and the increase in Bax expression in cancer cells, which improved the Bax/Bcl-2 ratio [14]. This evidence concerns the gene BCL2 and cancer.